GlassScriptPhysician profile
Pajman A Danai
NPI 1437180528
$8,944.74
in general payments reported to CMS, 2019-2025
39 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,247 · 2020: $2,495 · 2021: $1,672 · 2022: $155 · 2023: $528 · 2024: $815 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.42 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,504.60 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Glaxosmithkline, LLC. | $1,407.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,309.03 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Actelion Pharmaceuticals US, INC. | $642.08 | 2019-2025 | Opsumit, Opsynvi |
| Grifols USA, LLC | $503.21 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $438.21 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $318.08 | 2019-2025 | Dupixent |
| Harmony Biosciences LLC | $277.42 | 2020-2024 | Wakix |
| Jazz Pharmaceuticals INC. | $263.56 | 2019-2025 | |
| Inspire Medical Systems, INC. | $212.81 | 2023-2024 | Inspire |
| United Therapeutics Corporation | $195.44 | 2020-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $179.64 | 2021-2025 | Smartvest |
| Insmed, INC. | $162.32 | 2019-2025 | Brinsupri, Arikayce |
| Advanced Respiratory, INC | $141.77 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $140.60 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pajman Danai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.